A Rare Eye Disease Gene Therapy Shows Vision Gains in Every Patient Treated
Every patient in the first group improved, and no serious adverse events were recorded. The FDA has agreed on what a pivotal trial needs to show, and Phase 3 dosing is planned for 2027.